Diabetes Mellitus Outcome in Pancreatic Diseases the Missing Link between Type 1 and Type 2 Diabetes Mellitus

Aim: To study the features of pathogenesis, diagnosis and management of patients with diabetes, frolicking during various pathologies of the exocrine part of the pancreas.

Key points. Diabetes of the exocrine pancreas (DEP) is a common problem among patients with chronic pancreatitis, pancreatic cancer, hemochromatosis, after pancreatectomy. We discuss various aspects of this type of diabetes: its etiology, pathogenesis, diagnostic features, the importance of diagnosis for proper management. There are a comparative analysis of disorders of the relationship of various pancreatic hormones in DEP, their influence on the pathogenesis of the disease and clinical significance in the differential diagnosis of DEP with diabetes mellitus 1 and 2 types.

Conclusion. The increasing incidence of chronic and acute pancreatitis, better survival rates in patients with pancreatic cancer with the subsequent development of DEP, led to the evidence that the differential diagnosis of this disease, the development of guidelines for the management of such patients have become relevant. 

1. Dedov I.I., Shestakova M.V., Mayorov A.Yu., eds. Standards of specialized diabetes care. 10th ed. M.; 2021. 148 p. (in Russian). DOI: 10.14341/DM12802

2. Kononenko I.V., Smirnova O.M., Mayorov A.Yu., Shestakova M.V. Classification of diabetes. World Health Organization 2019. What’s new? Diabetes Mellitus. 2020;23(4):329–39. (in Russian). DOI: 10.14341/ DM12405

3. Wei Q., Qi L., Lin H., Liu D. et al. Pathological mechanisms in diabetes of the exocrine pancreas: what's known and what's to know. Front. Physiol. 2020;11:570276. DOI: 10.3389/fphys.2020.570276

4. Cui Y., Andersen D.K. Pancreatogenic diabetes: special considerations for management. Pancreatology. 2011;11(3):279–94. DOI: 10.1159/000329188

5. Malka D., Hammel F., Sauvanet A., Rufat P. et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology. 2000;119(5):1324–32. DOI: 10.1053/gast.2000.19286

6. Hardt P.D., Brendel M.D., Kloer H.U., Bretzel R.G. Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? Diabetes Care. 2008;31(suppl.2):S165–9. DOI: 10.2337/dc08-s244

7. Ciochina M., Balaban D.V., Manucu G., Jinga M. et al. The impact of pancreatic exocrine diseases on the β-cell and glucose metabolism — a review with currently available evidence. Biomolecules. 2022;12(5):618. DOI: 10.3390/biom12050618

8. Richardson A., Park W.G. Acute pancreatitis and diabetes mellitus: a review. Korean J. Intern. Med. 2021;36(1):15–24. DOI: 10.3904/ kjim.2020.505

9. Schrader H., Menge B.A., Schneider S., Belyaev O. et al. Reduced pancreatic volume and beta-cell area in patients with chronic pancreatitis. Gastroenterology. 2009;136(2):513–22. DOI: 10.1053/j.gastro.2008.10.083

10. Bellin M.D., Whitcomb D.C., Abberbock J., Sherman S. et al. Patient and disease characteristics associated with the presence of diabetes mellitus in adults with chronic pancreatitis in the United States. Am. J. Gastroenterol. 2017;112(9):1457–65. DOI: 10.1038/ajg.2017.181

11. Goodarzi M.O., Nagpal T., Greer P., Cui J. et al. Genetic risk score in diabetes associated with chronic pancreatitis versus type 2 diabetes mellitus. Clin. Transl. Gastroenterol. 2019;10(7):e00057. DOI: 10.14309/ctg.0000000000000057

12. Machicado J.D., Papachristou G.I. Pancreatogenic diabetes, acute pancreatitis management, and pancreatic tuberculosis: appraising the present and setting goals for the future. Unit. Eur. Gastroenterol. J. 2020;8(4):365–8. DOI: 10.1177/2050640620917017

13. Ragimov R.M. Exocrine function and structural features of pancreas in patients with type 1 and type 2 diabetes mellitus: abstract of cand. med. thesis. M.: Scientific and Research Institute of Endocrinology of the Ministry of Health of Russia; 2022. 25 p. (in Russian)

14. Ebert R., Creutzfeldt W. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia. 1980;19(3):198–204. DOI: 10.1007/BF00275269

15. Singh V.K., Haupt M.E., Geller D.E., Hall J.A. et al. Less common etiologies of exocrine pancreatic insufficiency. World. J. Gastroenterol. 2017;23(39):7059–76. DOI: 10.3748/wjg.v23.i39.7059

16. Kunovský L., Dítě P., Jabandžiev P., Eid M. et al. Causes of exocrine pancreatic insufficiency other than chronic pancreatitis. J. Clin. Med. 2021;10(24):5779. DOI: 10.3390/jcm10245779

17. Perbtani Y., Forsmark C.E. Update on the diagnosis and management of exocrine pancreatic insufficiency. F1000Res. 2019;8:F1000 Faculty Rev-1991. DOI: 10.12688/f1000research.20779.1

18. Lan X., Robin G., Kasnik J., Wong G. et al. Challenges in diagnosis and treatment of pancreatic exocrine insufficiency among patients with pancreatic ductal adenocarcinoma. Cancers (Basel). 2023;15(4):1331. DOI: 10.3390/cancers15041331

19. Duggan S.N., Ewald N., Kelleher L., Griffin O. et al. The nutritional management of type 3c (pancreatogenic) diabetes in chronic pancreatitis. Eur. J. Clin. Nutr. 2017;71(1):3–8. DOI: 10.1038/ejcn.2016.127

20. Rickels M.R., Bellin M., Toledo F.G., Robertson R.P. et al. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology. 2013;13(4):336–42. DOI: 10.1016/j.pan.2013.05.002

21. Nils E., Hardt P.D. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J. Gastroenterol. 2013;19(42):7276–81. DOI: 10.3748/wjg.v19.i42.7276

22. Pal P., Pramanik S., Ray S. Editor’s Pick: Disorders of gastrointestinal motility in diabetes mellitus: an unattended borderline between diabetologists and gastroenterologists. EMJ Diabet. 2021;9(1):64– 74. DOI: 10.33590/emjdiabet/21-00155

23. Hieronymus L., Griffin S. Role of amylin in type 1 and type 2 diabetes. Diabetes Educ. 2015;41(1suppl.):47S–56S. DOI: 10.1177/0145721715607642

24. Stanchev P.E., Orbetzova M.M., Terzieva D.D., Davcheva D.M. et al. Serum levels of incretin hormones — GLP-1 and GIP in patients with type 1 diabetes mellitus. Folia Med. (Plovdiv). 2019;61(1):76–83. DOI: 10.2478/folmed-2018-0056

25. Ghosh I., Mukhopadhyay P., Das K., Anne M.B. et al. Incretins in fibrocalculous pancreatic diabetes: a unique subtype of pancreatogenic diabetes. J. Diabetes. 2021;13(6):506–11. DOI: 10.1111/1753-0407.13139

26. Śliwińska-Mossoń M., Bil-Lula I., Marek G. The cause and effect relationship of diabetes after acute pancreatitis. Biomedicines. 2023;11(3):667. DOI: 10.3390/biomedicines11030667

27. Donowitz M., Hendler R., Spiro H.M., Binder H.J. et al. Glucagon secretion in acute and chronic pancreatitis. Ann. Intern. Med. 1975;83(6):778–81. DOI: 10.7326/0003-4819-83-6-778

28. Niwano F., Babaya N., Hiromine Y., Matsumoto I. et al. Glucose metabolism after pancreatectomy: opposite extremes between pancreaticoduodenectomy and distal pancreatectomy. J. Clin. Endocrinol. Metab. 2021;106(5):e2203–14. DOI: 10.1210/clinem/dgab036

29. Phillips A.R., Abu-Zidan F.M., Bonham M.J., Cooper G.J. et al. Amylin and severe acute pancreatitis. Pancreas. 2000;20(1):105–6. DOI: 10.1097/00006676-200001000-00015

30. Mezza T., Cefalo C.M.A., Cinti F., Quero G. et al. Endocrine and metabolic insights from pancreatic surgery. Trends Endocrinol. Metab. 2020;31(10):760–72. DOI: 10.1016/j.tem.2020.07.003

31. Lund A. On the role of the gut in diabetic hyperglucagonaemia. Dan. Med. J. 2017;64(4):B5340. 32. Wilmer A. ICU management of severe acute pancreatitis. Eur. J. Intern. Med. 2004;15(5):274–280. DOI: 10.1016/j.ejim.2004.06.004

32. Marques P., Barry S., Carlsen E., Collier D. et al. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. Endocr. Rel. Cancer. 2019;26(12):853–65. DOI: 10.1530/ERC-19-0327

33. Da Silva Xavier G. The cells of the islets of Langerhans. J. Clin. Med. 2018;7(3):54. DOI: 10.3390/jcm7030054

34. Xu W., Zhou Y.F., Xia S.H. Octreotide for primary moderate to severe acute pancreatitis: a meta-analysis. Hepatogastroenterology. 2013;60(126): 1504–8.

35. Pendharkar S.A., Asrani V.M., Xiao A.Y., Yoon H.D. et al. Relationship between pancreatic hormones and glucose metabolism: a crosssectional study in patients after acute pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2016;311(1):G50–8. DOI: 10.1152/ajpgi.00074.2016

36. Lytrivi M., Igoillo-Esteve M., Cnop M. Inflammatory stress in islet β-cells: therapeutic implications for type 2 diabetes? Curr. Opin. Pharmacol. 2018;43:40–5. DOI: 10.1016/j.coph.2018.08.002

37. Koopmans S.J., van Mansfeld A.D., Jansz H.S., Krans H.M. et al. Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues. Diabetologia. 1991;34(4):218–24. DOI: 10.1007/BF00405079

38. Westwell-Roper C., Dai D.L., Soukhatcheva G., Potter K.J. et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J. Immunol. 2011;187(5):2755–65. DOI: 10.4049/jimmunol.1002854

39. Malaisse-Lagae F., Stefan Y., Cox J., Perrelet A. et al. Identification of a lobe in the adult human pancreas rich in pancreatic polypeptide. Diabetologia. 1979;17(6):361–5. DOI: 10.1007/BF01236270

40. Marchetti P., Lupi R., Bugliani M., Kirkpatrick C.L. et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia. 2012;55(12):3262–72. DOI: 10.1007/s00125-012-2716-9

41. English A., Irwin N. Nonclassical islet peptides: pancreatic and extrapancreatic actions. Clin. Med. Insights Endocrinol. Diabetes. 2019;12:1179551419888871. DOI: 10.1177/1179551419888871